Geode Capital Management LLC grew its holdings in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 0.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,374,971 shares of the medical research company’s stock after purchasing an additional 24,453 shares during the quarter. Geode Capital Management LLC owned 2.57% of IQVIA worth $982,272,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in the business. Ameliora Wealth Management Ltd. acquired a new position in shares of IQVIA in the fourth quarter worth $25,000. International Assets Investment Management LLC purchased a new position in IQVIA in the fourth quarter valued at $27,000. Activest Wealth Management grew its stake in IQVIA by 590.0% during the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after purchasing an additional 118 shares in the last quarter. Physician Wealth Advisors Inc. increased its holdings in IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after purchasing an additional 134 shares during the period. Finally, Westside Investment Management Inc. raised its position in IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 101 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on IQV. BMO Capital Markets set a $250.00 target price on shares of IQVIA in a research note on Friday, February 6th. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Sunday, April 19th. UBS Group dropped their target price on IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a report on Friday, February 6th. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the stock from $174.00 to $213.00 in a report on Monday, March 9th. Finally, Stifel Nicolaus dropped their price objective on IQVIA from $273.00 to $220.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $225.69.
IQVIA Price Performance
Shares of IQV opened at $182.03 on Friday. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. IQVIA Holdings Inc. has a 1-year low of $136.41 and a 1-year high of $247.04. The stock has a market cap of $30.38 billion, a PE ratio of 22.56, a price-to-earnings-growth ratio of 1.73 and a beta of 1.18. The firm has a fifty day moving average price of $170.34 and a 200 day moving average price of $196.18.
IQVIA (NYSE:IQV – Get Free Report) last posted its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter in the previous year, the firm earned $2.70 earnings per share. The business’s revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current year.
IQVIA declared that its Board of Directors has approved a share repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.
IQVIA Profile
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
See Also
- Five stocks we like better than IQVIA
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
